The new iRECIST guideline—developed in consultation with academics, drug companies, and regulatory authorities—provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kinds of drugs.

©2017 American Association for Cancer Research.
2017
American Association for Cancer Research.
You do not currently have access to this content.